Navigating Complexity in Pulmonary Trials: Biomarker-Driven Approaches

This is article four in our series on smarter trial designs for complex pulmonary diseases. To view the full series as a PDF, download our Navigating Complexity in Pulmonary Trials whitepaper here.

1. Navigating Complexity in Pulmonary Trials
2. Adaptive Trial Design
3. Enrichment Strategies
4. Biomarker Driven Approaches

Welcome to the final article in our series on smarter trial designs for pulmonary diseases. We’ve talked about adaptive designs and enrichment strategies—now let’s dive into biomarkers, which are rapidly transforming how we design, execute, and interpret clinical trials in Idiopathic Pulmonary Fibrosis (IPF), Acute Respiratory Distress Syndrome (ARDS), and Cystic Fibrosis (CF). If you’re a Sponsor navigating these complex indications, biomarker-driven approaches can help you stratify patients, refine endpoints, and guide adaptive decisions, all while improving trial efficiency and precision.

Exploring Biomarkers in Pulmonary Trials

Biomarkers are measurable indicators of biological processes, disease states, or therapeutic responses. In pulmonary trials, they can be:

• Diagnostic – Identifying disease presence (e.g., cystic fibrosis transmembrane conductance regulator CFTR mutations in CF)
• Prognostic – Predicting disease progression (e.g., serum surfactant proteins in IPF)
• Predictive – Indicating likely response to treatment (e.g., cytokine profiles in ARDS)
• Pharmacodynamic – Reflecting biological response to therapy (e.g., sweat chloride in CF)

Biomarkers help Sponsors reduce noise in outcome measures, target therapies to responsive subgroups, accelerate timelines by detecting early signals, and support regulatory submissions with mechanistic data. However, biomarker-driven trials also require careful planning: validation, standardization, and regulatory alignment are essential to success.

Biomarker-Driven Approaches for Pulmonary Studies: A Real-World Look

IPF – Biomarker Integration in the INMARK Trial

The INMARK trial evaluated nintedanib in IPF patients using serum biomarkers like SP-D and MMP-7. These markers helped detect early treatment effects, stratify patients by fibrosis burden, and guide adaptive decisions.

Takeaway: Biomarkers can improve signal detection and reduce reliance on slow-changing endpoints like Forced Vital Capacity (FVC).

CF – Sweat Chloride and Genotype Selection

In CF trials, sweat chloride is a validated pharmacodynamic marker for CFTR function. Sponsors like Vertex have used it alongside genotype-based enrollment to demonstrate efficacy in targeted populations, support accelerated approval pathways, and monitor early response to therapy.

Takeaway: Combining genetic and functional biomarkers strengthens both trial design and regulatory positioning.

ARDS – Cytokine-Guided Subphenotyping

Recent ARDS trials have used inflammatory biomarkers (IL-6, IL-8, TNF-α) to identify hyperinflammatory subgroups. These subphenotypes respond differently to anti-inflammatory therapies, require tailored randomization strategies, and benefit from adaptive designs.

Takeaway: Biomarker-guided stratification can unlock treatment effects hidden in heterogeneous populations.

Emerging Trend: Digital and Composite Biomarkers

Sponsors are increasingly integrating digital biomarkers, data from wearables, apps, and remote sensors. These tools offer continuous, real-world insights, reduced patient burden, and enhanced retention.

An example of this can be found in CF, where sponsors may choose to combine sweat chloride with home spirometry and symptom tracking to provide a multidimensional view of treatment response.

Final Thought

As you plan your biomarker-driven trial, PharPoint can support your team with protocol design, central lab coordination, site training, real-time data analytics, and digital integration.